Nelfinavir (AG 1343) Mesylate

For research use only.

Catalog No.S4282 Synonyms: Viracept

8 publications

Nelfinavir (AG 1343) Mesylate Chemical Structure

CAS No. 159989-65-8

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Selleck's Nelfinavir (AG 1343) Mesylate has been cited by 8 publications

Antimicrob Agents Chemother, 2020, AAC.00872-20

PubMed: 32669265 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, AAC.01002-20

PubMed: 32601166 ( click the link to review the publication )

Leukemia, 2019, 33(1):37-51

PubMed: 29884901 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3757-3765

PubMed: 31262902 ( click the link to review the publication )

Immunity, 2018, 49(5):842-856

PubMed: 30366764 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):236

PubMed: 30241558 ( click the link to review the publication )

Pharm Res, 2011, 28(2):337-63

PubMed: 20945153 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HIV Protease Inhibitors

Biological Activity

Description

Nelfinavir Mesylate (Viracept, AG1343) is a potent HIV protease inhibitor with K_i of 2 nM.

Targets

HIV protease ^[1]
(Cell-free assay)

2 nM(Ki)

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HeLa	M1vBUWZ2dmO2aX;uJIF{e2G7			MYTUVH9VWkGQU2DPVnRGWjpiaX7obYJqfGmxbjDv[kBVTUFidYD0ZYtmKCiWRVG6JFExKHWPKTDpckBQS1RzLXX4dJJme3OrbnegTIVN[SClZXzsd{whUUN3ME2yNU45\|ryPLh?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZ6MUO3PEc,OTB4OEGzO\|g9N2F-
Caco-2	NID6VmRHfW6ldHnvckBie3OjeR?=			MmXEWHBgXFKDTmPQU3JVTVJ8IHnubIljcXSrb36gc4YhTGG3bn;yeYJq[2mwIITyZY5{\XCrdHjlcIlidCC2cnHud5BwenRiKHLhd4FtKHSxIHHwbYNidCliKFTheY5wenWkaXPpclohPSC3TTmgbY4hS2Glbz2yJINmdGy\|LDDJR\|UxRTFwNN88UU4>	M2P1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOEKwNVM4Lz5zMEiyNFE{PzxxYU6=
MT-4	NEfW[2lCdnSrdnnyZYwh[XO\|YYm=			NGHSZYVCdnSrLVjJWk0yKGGldHn2bZR6KGGpYXnud5QhX2muZDD0fZBmKH[rcoXzJIlvKE2WLUSgZ4VtdHNuIFXEOVA:OC5yMt88UU4>	NGS4Vog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUW0N\|Y4Pyd-MUG1OFM3Pzd:L3G+
MT-4	Mk\pRY51cX[rcnHsJIF{e2G7			M{X5cWFvfGlvSFnWMVEh[WO2aY\peJkh[WejaX7zeEBufXSjboSgTGlXNTFiaX6gUXQuPCClZXzsd{ApdXW2YYTpc44he2WuZXP0[YQhf2m2aDDjc41xd3WwZDCxLUwhTUR3ME2wMlA4\|ryPLh?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTV2M{[3O{c,OTF3NEO2O\|c9N2F-
MT-4	M4nZ[WFvfGm4aYLhcEBie3OjeR?=			NVjheFdjSW62aT3ITXYuOSCjY4Tpeol1gSCjZ3HpcpN1KG23dHHueEBJUVZvMTDpckBOXC12IHPlcIx{KCivdYTheIlwdiC\|ZXzlZ5Rm\CC5aYToJJJqfG:wYY\pdkktKEWGNUC9NE4yOc7:TT6=	NEDsRVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUW0N\|Y4Pyd-MUG1OFM3Pzd:L3G+
MT-4	NWDlcXE6SW62aY\pdoFtKGG\|c3H5			MUnBcpRqNUiLVj2xJIFkfGm4aYT5JIFo[Wmwc4SgcZV1[W62IFjJWk0yKGmwIF3UMVQh[2WubIOgLI12fGG2aX;uJJNmdGWldHXkJJdqfGhic3HxeYlv[X[rcjmsJGVFPTB;MD6xNu69VS5?	M2DPdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNUSzOlc4Lz5zMUW0N\|Y4PzxxYU6=
MT-4	NXHFcHdDSW62aY\pdoFtKGG\|c3H5			M{OzXmFvfGlvSFnWMVEh[WO2aY\peJkh[WejaX7zeEBufXSjboSgTGlXNTFiaX6gUXQuPCClZXzsd{ApdXW2YYTpc44he2WuZXP0[YQhf2m2aDDu[YxncW6jdnnyLUwhTUR3ME2yMlQ1\|ryPLh?=	NWrJc2ZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1OFM3PzdpPkGxOVQ{Pjd5PD;hQi=>
LLC-PK1	M1zCeGZ2dmO2aX;uJIF{e2G7			MnvhTY5pcWKrdHnvckBw\iCSLXfsfYNweHKxdHXpckwhdW:3c3WgUE1u\HJzYTDlfJBz\XO\|ZXSgbY4hVEyFLWDLNUBmeGm2aHXsbYFtKGOnbHzzJJV{cW6pIHPhcINmcW5vQV2gdI9t[XKrc3H0bY9vKGG\|c3H5MEBKSzVyPUKuN:69VS5?	NFrGV\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[5PVM5QSd-MUK2PVk{QDl:L3G+
LLC-PK1	MYfGeY5kfGmxbjDhd5NigQ>?			NX34dmc2XFChVGLBUnNRV1KWRWK6JIlvcGmkaYTpc44hd2ZiQ3HsZ4Vqdi2DTTDl[oZtfXhiaX6gUYRzOWFvZYjwdoV{e2mwZzDMUGMuWEtzIHPlcIx{NCCLQ{WwQVIvO87:TT6=	NYLJOZoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2PVk{QDlpPkGyOlk6Ozh7PD;hQi=>
LLC-PK1	MVzGeY5kfGmxbjDhd5NigQ>?			NGPnOYJKdmirYnn0bY9vKG:oIGCt[4x6[2:ycn;0[YlvNCCqdX3hckBNNU2GUkGg[ZhxemW\|c3XkJIlvKEyOQz3QT\|Eh\XCrdHjlcIlidCClZXzsd{B2e2mwZzDjZYxk\WmwLVHNJJBwdGG{aYPheIlwdiCjc4PhfUwhUUN3ME2zMlTPxE1w	NFPpdlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[5PVM5QSd-MUK2PVk{QDl:L3G+
LLC-PK1	MYHGeY5kfGmxbjDhd5NigQ>?			NVHnZYpQXFChVGLBUnNRV1KWRWK6JIlvcGmkaYTpc44hd2ZiQ3HsZ4Vqdi2DTTDl[oZtfXhiaX6gUWRTOS2neIDy[ZN{cW6pIFzMR{1RUzFiY3XscJMtKEmFNUC9N{41\|ryPLh?=	NWL1dVlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2PVk{QDlpPkGyOlk6Ozh7PD;hQi=>
HEK	NVXYRmhwTnWwY4Tpc44h[XO\|YYm=			MnLuWHBgXFKDTmPQU3JVTVJ8IHnuZ5Jm[XOnIHnuJI1qfG:6YX70do9v\SCrboTyZYNmdGy3bHHyJIFk[3WvdXzheIlwdiCrbjDCR3JRNWW6cILld5NqdmdiSFXLJINmdGy\|LDDJR\|UxRTF{LkZOwG0v	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTByN{GwNkc,OTVyMEexNFI9N2F-
CEM-SS	NYrXdI57SW62aY\pdoFtKGG\|c3H5		M1nWNlYh\GG7cx?=	NX7UNJVGSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCqdX3hckBETU1vU2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIFnfGW{IE[g[IF6eyCkeTDNWHMh[XO\|YYmsJGVFPTB;MD6wN:69VS5?	M{j5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MkG3NlgyLz5zNUKxO\|I5OTxxYU6=
HOG.R5	MW\BcpRqfmm{YXygZZN{[Xl?		MVe0JIRigXN?	MXzBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIFjPS{5TPSClZXzsd{Bi\nSncjC0JIRigXNuIFnDOVA:OC5yOd88UU4>	MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV{MUeyPFEoRjF3MkG3NlgyRC:jPh?=
MT-4	NWHpN3ljTnWwY4Tpc44h[XO\|YYm=			NGHrZZlG\m[nY4TpeoUh\G:\|ZTDv[kBkd22yb4Xu[EBz\XG3aYLl[EB1dyCrbnjpZol1KHKncHzpZ4F1cW:wIH;mJIh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhfHmyZTCxJIlvKE2WLUSgZ4VtdHNuIFXEOVA:OC5yMt88UU4>	NYPCV4RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1N\|c{PTBpPkG1OVM4OzVyPD;hQi=>
MT4	MlnDRY51cX[rcnHsJIF{e2G7			M4\IcWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiSGjCNkBqdiCPVESgZ4VtdHNuIFnDOVA:OC5\|Mt88UU4>	M3:4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEW4OVA2Lz5zNkS1PFUxPTxxYU6=
MT4	NXfSWpcxSW62aY\pdoFtKGG\|c3H5			MYPBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEWSMUOgbY4hVVR2IHPlcIx{NCCLQ{WwQVAvPDYQvF2u	NVL3ZmI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0OVg2ODVpPkG2OFU5PTB3PD;hQi=>
PHA-PBMC	MWrBcpRqfmm{YXygZZN{[Xl?			MlPsRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCEQT3MJIl{d2yjdHWgbY4hcHWvYX6gVGhCNVCETVOgZ4VtdHNuIFnDOVA:OC5yMEhOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjlzM{exOEc,OTZ7MUO3NVQ9N2F-
MT2	M1jZfGFvfGm4aYLhcEBie3OjeR?=			NETVTIJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIFzBTUBqe2:uYYTlJIlvKGi3bXHuJG1VOiClZXzsd{whUUN3ME2wMlAy\|ryPLh?=	MkDXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NVQoRjF4OUGzO\|E1RC:jPh?=
PHA-PBMC	M2XZbmFvfGm4aYLhcEBie3OjeR?=			M{LqXGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTFHJJIl{d2yjdHWgbY4hcHWvYX6gVGhCNVCETVOgZ4VtdHNuIFnDOVA:OC5yMUVOwG0v	MnjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NVQoRjF4OUGzO\|E1RC:jPh?=
MT2	NWfkb21ySW62aY\pdoFtKGG\|c3H5			Mm\3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOiCHSF:gbZNwdGG2ZTDpckBpfW2jbjDNWFIh[2WubIOsJGlEPTB;MD6wNu69VS5?	MmDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NVQoRjF4OUGzO\|E1RC:jPh?=
PHA-PBMC	MkTQRY51cX[rcnHsJIF{e2G7			Mlr2RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgcZVtfGliZIL1[{1z\XOrc4ThcpQhUEmYMTDFWEB3[XKrYX70JIlvKGi3bXHuJHBJSS2SQl3DJINmdGy\|LDDJR\|UxRTBwMEOy{txONg>?	MmnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NVQoRjF4OUGzO\|E1RC:jPh?=
PHA-PBMC	NXPQR\|k6SW62aY\pdoFtKGG\|c3H5			NX23bYRPSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhdXWudHmg[JJ2\y2{ZYPpd5RidnRiSFnWNUBIKH[jcnnhcpQhcW5iaIXtZY4hWEiDLWDCUWMh[2WubIOsJGlEPTB;MD6xO:69VS5?	NHX3dm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmxN\|cyPCd-MU[5NVM4OTR:L3G+
PHA-PBMC	NHPTNZdCdnSrdnnyZYwh[XO\|YYm=			MlzORY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgcZVtfGliZIL1[{1z\XOrc4ThcpQhUEmYMTDDJJZiemmjboSgbY4hcHWvYX6gVGhCNVCETVOgZ4VtdHNuIFnDOVA:OC5\|Md88UU4>	M2X6[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUGzO\|E1Lz5zNkmxN\|cyPDxxYU6=
MT2	MWHBcpRqfmm{YXygZZN{[Xl?			NHjD[lRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZ{IFXIU{BqdiCPVEKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wN:69VS5?	NVG5XJFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT2	NEnMdZNCdnSrdnnyZYwh[XO\|YYm=			M4\4UmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTFHJJIlvKE2WMjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkCzNu69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	NGXlelRCdnSrdnnyZYwh[XO\|YYm=			NVTRT5RvSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCrbjDNWFQh[2WubIOgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODN\|zszNMi=>	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	MYrBcpRqfmm{YXygZZN{[Xl?			MXrBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEeUTEm4NFY2eDJyIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDlfJBz\XO\|aX;uJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjB6zszNMi=>	M2\V[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	NHjr[G9CdnSrdnnyZYwh[XO\|YYm=			M{n2R2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJJqfG:wYY\pdk1z\XOrc4ThcpQhUEmYMTDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC5{Md88UU4>	M1rP[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	MWrBcpRqfmm{YXygZZN{[Xl?			M{naS2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JIFueHKnbnH2bZIuemW\|aYP0ZY51KEiLVkGgbY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJIV5eHKnc4Ppc44h[nliTWTUJIF{e2G7LDDFR\|UxRTBwMkNOwG0v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT2	MYHBcpRqfmm{YXygZZN{[Xl?			M2PndGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjJiUl;EJIlvKE2WMjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkK0{txONg>?	NIXKcHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O3NVgyOSd-MUezO\|E5OTF:L3G+
MT4	NH7reZVCdnSrdnnyZYwh[XO\|YYm=			NHfadldCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBifGG8YX7heolzNXKnc3nzeIFvfCCKSW[xJIlvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBmgHC{ZYPzbY9vKGK7IF3UWEBie3OjeTygSWM2OD1yLkK3{txONg>?	M4fx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{exPFEyLz5zN{O3NVgyOTxxYU6=
MT4	M4PqdWFvfGm4aYLhcEBie3OjeR?=			NUC1PYg3SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDHVmw6QDB4NYCzNEBqdiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4h\XiycnXzd4lwdiCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6yO:69VS5?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MXvBcpRqfmm{YXygZZN{[Xl?			MVvBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEeUTEm4NFY2eDRyIHnuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJAzPCCJYXegdJJwfGWrbjDlfJBz\XO\|aX;uJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjN2zszNMi=>	NUjWR3VvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT4	MV7BcpRqfmm{YXygZZN{[Xl?			NXLwNm06SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhcWSrbnH2bZIuemW\|aYP0ZY51KEiLVkGgbY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJIV5eHKnc4Ppc44h[nliTWTUJIF{e2G7LDDFR\|UxRTBwNEhOwG0v	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MVvBcpRqfmm{YXygZZN{[Xl?			MkPHRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sgd4FyfWmwYY\pdk1z\XOrc4ThcpQhUEmYMTDpckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6g[ZhxemW\|c3nvckBjgSCPVGSgZZN{[XluIFXDOVA:OC52ON88UU4>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN5MUixNUc,OTd\|N{G4NVE9N2F-
MT4	MXfBcpRqfmm{YXygZZN{[Xl?			MWHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDsc5BqdmG4aYKtdoV{cXO2YX70JGhKXjFiaX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gdFI1KEejZzDwdo91\WmwIHX4dJJme3Orb36gZpkhVVSWIHHzd4F6NCCHQ{WwQVAvPDoQvF2u	NUHFPINURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezO\|E5OTFpPkG3N\|cyQDFzPD;hQi=>
MT2	M4K3cGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NWq1b2g5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVVR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJIV5eHKnc4Ppc44h[nliTWTUJIF{e2G7LDDDR\|UxRThwMd88UU4>	MlPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|N{G4NVEoRjF5M{exPFEyRC:jPh?=
MT4	MXTBcpRqfmm{YXygZZN{[Xl?			MkHYRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpckBOXDRiY3XscJMh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEG2{txONg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV\|N{[yPEc,OTd3M{e2Nlg9N2F-
MT4	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=			NXexTYY5S3m2b4TvfIlkcXS7IHHnZYlve3RiTWS0JINmdGy\|IHL5JG1VXCCjc4PhfUwhVEN3ME2xNe69VS5?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV\|N{[yPEc,OTd3M{e2Nlg9N2F-
MT4	NWfnWJRWSW62aY\pdoFtKGG\|c3H5		M4C1SFUh\GG7cx?=	MoHzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJZqenW\|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjBzON88UU4>	NIrlNo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W3Olg1QCd-MUe1O\|Y5PDh:L3G+
MT4	MUjBcpRqfmm{YXygZZN{[Xl?		NGS5[3U2KGSjeYO=	NFTjNnpCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZ{IF3TJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCjZoTldkA2KGSjeYOgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODR6zszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5Nki0PEc,OTd3N{[4OFg9N2F-
CEM	M4ruTmFvfGm4aYLhcEBie3OjeR?=		NILsNHM4KGSjeYO=	MX7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYzKFKRRDD3bZRpKHC{b4TlZZNmKEdzN16vWlQ4SSCvdYTheIlwdiCrbn\lZ5Rm\CCrbjDoeY1idiCFRV2gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{Bxem:mdXP0bY9vKGGodHXyJFch\GG7czDifUBN\W62aT3SWEBi[3Srdnn0fUBie3OjeTygSWM2OD1yLkJOwG0v	NUniTmdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	MkD4RY51cX[rcnHsJIF{e2G7		MXu3JIRigXN?	NYW2V2dnSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2Qhf2m2aDDwdo91\WG\|ZTDWOFdCKG23dHH0bY9vKGmwZnXjeIVlKGmwIHj1cYFvKEOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzJJBzd2S3Y4Tpc44h[W[2ZYKgO{Bl[Xm\|IHL5JGxmdnSrLWLUJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwMUe3{txONg>?	NVzpXWZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1O\|Y5PDhpPkG3OVc3QDR6PD;hQi=>
CEM	MlrGRY51cX[rcnHsJIF{e2G7		MX63JIRigXN?	NVfGTFZISW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMjDSU2Qhf2m2aDDwdo91\WG\|ZTDHNVdPKG23dHH0bY9vKGmwZnXjeIVlKGmwIHj1cYFvKEOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzJJBzd2S3Y4Tpc44h[W[2ZYKgO{Bl[Xm\|IHL5JGxmdnSrLWLUJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwMUm5{txONg>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV5Nki0PEc,OTd3N{[4OFg9N2F-
CEM	Mn\FRY51cX[rcnHsJIF{e2G7		MXG3JIRigXN?	NVW4XIZGSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEiLVkKgVm9FKGmwZnXjeIVlKGmwIHj1cYFvKEOHTTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzJJBzd2S3Y4Tpc44h[W[2ZYKgO{Bl[Xm\|IHL5JGxmdnSrLWLUJIFkfGm4aYT5JIF{e2G7LDDFR\|UxRTBwMkix{txONg>?	M2LhRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUe2PFQ5Lz5zN{W3Olg1QDxxYU6=
HEK293	NFfpUGFCdnSrdnnyZYwh[XO\|YYm=		Moe0OFghcHK\|	MmLpRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiTly0MVMhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDy[ZBtcWOjdHnvck1l\W[oZXP0bZZmKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[U1j[XOnZDDwbIVvd3S7cHnjJIF{e2G7LDDFR\|UxRTBwMEC1PO69VS5?	NHLxdFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[zPFY6PCd-MUe2N\|g3QTR:L3G+
MT4	MlT3RY51cX[rcnHsJIF{e2G7		NI\HfnQ3KGSjeYO=	M1PNWWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIF3UOEBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDFR\|UxRTBwMEK5{txONg>?	NXiycFRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2N\|g3QTRpPkG3OlM5Pjl2PD;hQi=>
MT4	M3ToZWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUf4NHc2PiCmYYnz	NHSxXlZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXDRiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhS0N3ME24{txONg>?	M2\qZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkO4Olk1Lz5zN{[zPFY6PDxxYU6=
HEK293	NVH3NlA4TnWwY4Tpc44h[XO\|YYm=	MUOwMlEzKHWP		MonsTY5pcWKrdHnvckBw\iCKSW[xJG5NPC1\|IIDyc5RmcW6\|IHnuZ49zeG:{YYTpc44hcW62bzD2bZJqd26\|IITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{B2dnC{b3Pld5Nm\CCpcEG2NEBGdnZicILveIVqdiCjdDCwMlEzKHWPIHL5JHdme3Sncn6gZoxwfA>?	M2HtWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkS2OFExLz5zN{[0OlQyODxxYU6=
HEK293	MoPWSpVv[3Srb36gZZN{[Xl?	MmjsNE4yOiC3TR?=		NEDoZnVKdmirYnn0bY9vKG:oIFjJWlEhVkx2LUOgdJJwfGWrboOgbY5kd3Kyb4LheIlwdiCrboTvJJZqemmxboOgeJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W\|c3XkJIF{KGGkZYLyZY51KEWwdjDwdo91\WmwIHH0JFAvOTJidV2gZpkhX2W\|dHXyckBjdG:2	M1TaO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkS2OFExLz5zN{[0OlQyODxxYU6=
MDCK2	NIXpRVFKdmirYnn0bY9vKG:oIHj1cYFv			NXvCfYxlUW6qaXLpeIlwdiCxZjDoeY1idiCPRGKxMYRmeGWwZHXueEBi[2O3bYXsZZRqd25ib3[gZ4Ft[2Wrbj3BUUBmgHC{ZYPz[YQhcW5iTVTDT\|Ih[2WubIOsJGlEPTB;MUmuPe69VS5?	NFKw[Wc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2OFMzPyd-MUe2OlQ{Ojd:L3G+
MDR1	Mo\zSpVv[3Srb36gZZN{[Xl?	MVOyNEB2VQ>?		MYPE[YNz\WG\|ZTDpckBRNWeueXPvdJJwfGWrbj3t[YRq[XSnZDD0[Y5w\m:4aYKg[Il{d3C{b4jpcEBnfW2jcnH0[UBm\m[udYigbY4hVUSFS{Kg[ZhxemW\|c3nu[{BpfW2jbjDNSHIyKGOnbHzzJIF1KDJyIIXN	NXHJTHBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2OlQ{OjdpPkG3OlY1OzJ5PD;hQi=>
CEM-SS	M{H0dmFvfGm4aYLhcEBie3OjeR?=		MYC1JIRigXN?	MUXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKEyDSTDpcoZm[3SnZDDpckBpfW2jbjDDSW0uW1NiY3XscJMh[XO\|ZYPz[YQh[XNicnX2[ZJ{\SC2cnHud4NzcXC2YYPlJIFkfGm4aYT5JIFnfGW{IEWg[IF6eyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wNFLPxE1w	NVLsdI8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVA6PTVpPkG3PVUxQTV3PD;hQi=>
MOLT-4/3B	M{PIbmFvfGm4aYLhcEBie3OjeR?=		MnnYOEBl[Xm\|	NXy4Tld2SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBqdm[nY4Tl[EBqdiCPT1zUMVQwO0JiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBu[XS3cnWgeolzfXNicnXs[YF{\SCvZXHzeZJm\CCjZoTldkA1KGSjeYOgc4YhcW6oZXP0bY9vKGK7IGLUJIF{e2G7LDDFR\|UxRTBwMEK5{txONg>?	NGT6fIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxOlUzOSd-MUizNVY2OjF:L3G+
MT4	NGDP[YlCdnSrdnnyZYwh[XO\|YYm=			Mnz4RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSB\|QjDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidC2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBu\XSqb3SsJGVEPTB;MD6wNVbPxE1w	Mn3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Mk[xPVUoRjF6NEK2NVk2RC:jPh?=
MT4	MW\DfZRwfG:6aXPpeJkh[XO\|YYm=			MmXaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIJ6KE2WVDDhd5NigSxiQ1O1NF0yOc7:TT6=	NWO2VnN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlYyQTVpPkG4OFI3OTl3PD;hQi=>
MT4	NVmzOmFtSW62aYLleJJwfmm{YXygZZN{[Xl?			NGfzTY1CdnSrcnX0do93cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFj1cYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgNUBPVDRwMzDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpcWNiZX\m[YN1KGK7IF3UWEBie3OjeTygSWM2OD1yLkCyN:69VS5?	MonsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	M3zxSGFvfGm{ZYTyc5ZqemGuIHHzd4F6			NX2ydmc1SW62aYLleJJwfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJFEhO0JiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyeZMucW6mdXPl[EBkgXSxcHH0bIlkKGWoZnXjeEBjgSCPVGSgZZN{[XluIFXDOVA:OC5yMklOwG0v	MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	NUj1dmNLSW62aY\pdoFtKGG\|c3H5			MlHIRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgVoV3\XK\|ZTD0doFve2O{aYD0ZZNmKGmwaHnibZRwei2{ZYPpd5RidnRiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCxJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYomgUXRVKGG\|c3H5MEBGSzVyPUCuNFI6\|ryPLh?=	Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	NX\3W5VKSW62aY\pdoFtKGG\|c3H5			NFzCO4tCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBvd25iboXjcIVwe2mmZTDy[ZZmenOnIITyZY5{[3KrcIThd4UhcW6qaXLpeI9zNXKnc3nzeIFvfCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW\|IEGgbY5n\WO2ZXSgbY4hcHWvYX6gUXQ1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolzfXNvaX7keYNm\CCleYTvdIF1cGmlIHXm[oVkfCCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wN\|XPxE1w	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV2MUeyOkc,OTh3NEG3NlY9N2F-
MT4	MkiwRY51cXKndILveolz[WxiYYPzZZk>			M4PTZWFvfGm{ZYTyc5ZqemGuIHHjeIl3cXS7IHHnZYlve3RiSIXtZY4hcW2vdX7v[IVncWOrZX7jfUB3cXK3czCyJGVJVyCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjB2Od88UU4>	Mn3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NEG3NlYoRjF6NUSxO\|I3RC:jPh?=
MT4	NXji[VBpSW62aYLleJJwfmm{YXygZZN{[Xl?			MmHmRY51cXKndILveolz[WxiYXP0bZZqfHliYXfhbY5{fCCKdX3hckBqdW23bn;k[YZq[2mnbnP5JJZqenW\|IEKgVm9FKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZpkhVVSWIHHzd4F6NCCHQ{WwQVAvODYQvF2u	NF;K[Ik9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW0NVczPid-MUi1OFE4OjZ:L3G+
MT4	NHX0TlFCdnSrcnX0do93cXKjbDDhd5NigQ>?			NUH2U\|VGSW62aYLleJJwfmm{YXygZYN1cX[rdImgZYdicW6\|dDDTbY1q[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{BOSUNiMkWxJIlv\mWldHXkJIlvKGi3bXHuJG1VPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW\|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYomgUXRVKGG\|c3H5MEBGSzVyPUCuNFXPxE1w	NY\Nd2hERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OFE4OjZpPkG4OVQyPzJ4PD;hQi=>
MT4	MmDTRY51cX[rcnHsJIF{e2G7			MWTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDQdo91\WG\|ZTDpcohq[mm2b4KtdoV{cXO2YX70JGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIJ6KE2WVDDhd5NigSxiRVO1NF0xNjF5zszNMi=>	NVnIVY5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OFE4OjZpPkG4OVQyPzJ4PD;hQi=>
MT4	NVvXTVA1SW62aY\pdoFtKGG\|c3H5	MYm1JJVO		MneyRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDFyRj;MN\|NHN012NlmvTVQ4Xi:TNUjFM3Y5OklxSUi0Wk9KQDWYIHHtbY5wKGGlaXSgd5Vje3SrdIX0bY9vKGmwIIDyc5Rm[XOnIHXuZ49lcW6pIILl[4lwdiCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyMkSgS4FoKHC{b4TlbY4heHKxZIXjeIlwdiC\|ZXzlZ5Rm\CCjdDC1JJVOKG:oIFfSUE0xOjB\|MTDifUBGNCCHQ{WwQVAvODFzzszNMi=>	MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	NX;HcFdoSW62aY\pdoFtKGG\|c3H5			NF73RmRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDnZYcheHKxdHXpckBxem:mdXP0bY9vKGK7IFXMTXNCNCCHQ{WwQVAvODF6zszNMi=>	NEi0eIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
MT2	MlXQRY51cX[rcnHsJIF{e2G7		MXK3JIRigXN?	MmHCRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCOQVmgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIFnfGW{IEeg[IF6eyCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wNlPPxE1w	M3\LOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	NXyxUpJSSW62aY\pdoFtKGG\|c3H5	MnrnOUB2VQ>?		NXr3fZpVSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDOUFQuOyCqYYLic5JqdmdiTEGwSk9XOzKLL120OmkwUTV2TT:vRVcyXi:LOETWJIFucW6xIHHjbYQhe3Wkc4TpeJV1cW:wIHnuJJBzd3SnYYPlJIVv[2:maX7nJJJm\2mxbjDpcoZm[3SnZDDpckBpfW2jbjDNWFQh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDwNlQhT2GpIIDyc5RmcW5icILv[JVkfGmxbjDz[Yxm[3SnZDDheEA2KHWPIH;mJIFueHKnbnH2bZIh[nliRVzJV2EtKEWFNUC9NE4yP87:TT6=	Mn\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7NUW1NVgoRjF6OUW1OVE5RC:jPh?=
MT4	MmX0RY51cX[rcnHsJIF{e2G7	NV34OW1kOSC3TR?=		MnjqRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDJ\|ST;LOFNKN012NlmvTVUxVC:JNUHBM2E4OVZiYX3pco8h[WOrZDDzeYJ{fGm2dYTpc44hcW5icILveIVie2ViZX7jc4RqdmdicnXnbY9vKGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB{NDDHZYcheHKxdHXpckBxem:mdXP0bY9vKHOnbHXjeIVlKGG2IEGgeW0hd2ZiYYThfoFv[X[rcjDifUBGVEmVQTygSWM2OD1yLkKx{txONg>?	NEnxRlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm1OVUyQCd-MUi5OVU2OTh:L3G+
MT4	NWXkPVl{SW62aY\pdoFtKGG\|c3H5	MYG1JJVO		MnPLRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVTR4ST;WPFJHN0l6NG[gZY1qdm9iYXPp[EB{fWK\|dHn0eZRqd25iaX6gdJJwfGWjc3Wg[Y5kd2SrbnegdoVocW:wIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIICyOEBI[WdicILveIVqdiCycn;keYN1cW:wIIPlcIVkfGWmIHH0JFUhfU1ib3[gdol1d26jdnnyJIJ6KEWOSWPBMEBGSzVyPUCuNlTPxE1w	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3NUWxPEc,OTh7NUW1NVg9N2F-
MT4	M{n5TGFvfGm4aYLhcEBie3OjeR?=	MoraOUB2VQ>?		MVjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKE6OND2zJIhiemKxcnnu[{BNOTCLL1e0PHYwUTV2Vj;MPVBOKGGvaX7vJIFkcWRic4Xid5RqfHW2aX;uJIlvKHC{b4TlZZNmKGWwY3;kbY5oKHKnZ3nvckBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6gdJJw\HWldHnvckB{\WynY4Tl[EBifCB3IIXNJI9nKHOjcYXpcoF3cXJiYomgSWxKW0FuIFXDOVA:OC5\|Mt88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3NUWxPEc,OTh7NUW1NVg9N2F-
MT4	NV;lTXhsSW62aY\pdoFtKGG\|c3H5	Mme3NUB2VQ>?		Mli1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCQTEStN{Bp[XKkb4LpcochVDFyRj;NOFZKN0l3NG[vWlgzSSCjbXnuc{Bi[2mmIIP1ZpN1cXS3dHnvckBqdiCycn;0[YF{\SCnbnPv[Ilv\yC{ZXfpc44hcW6oZXP0[YQhcW5iaIXtZY4hVVR2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDJ2IFfh[{Bxem:2ZXnuJJBzd2S3Y4Tpc44he2WuZXP0[YQh[XRiMTD1UUBw\iCOb4DpcoF3cXJiYomgSWxKW0FuIFXDOVA:OC53Md88UU4>	M364XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUW1OVE5Lz5zOEm1OVUyQDxxYU6=
MT4	NUDHXIk3SW62aY\pdoFtKGG\|c3H5	MkTnOUB2VQ>?		NIPON3hCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIF7MOE0{KGijcnLvdolv\yCOMUDGM2wzPElxTUS2TU9NPjOSL1G3NXYwTzd\|Uz;WPFJVKGGvaX7vJIFkcWRic4Xid5RqfHW2aX;uJIlvKHC{b4TlZZNmKGWwY3;kbY5oKHKnZ3nvckBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxOjRiR3HnJJBzd3SnaX6gdJJw\HWldHnvckB{\WynY4Tl[EBifCB3IIXNJI9nKGmwZHnuZZZqeiCkeTDFUGlUSSxiRVO1NF0xNjZ3zszNMi=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3NUWxPEc,OTh7NUW1NVg9N2F-
HeLa	M2e4cmFvfGm4aYLhcEBie3OjeR?=		MoS2O\|IhcHK\|	Mlj3RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCqYYLic5JqdmdiY3Hwd4llKEl{MEHWJI12fGGwdDDwdo91\WmwIHnu[oVkfGWmIHnuJIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5idnnyZYwhcW6oZXP0bY9vKGGodHXyJFczKGi{czDifUBj\XSjLXfhcIFkfG:\|aXThd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzM988UU4>	NIXZdGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiwOVU4OSd-MUm4NFU2PzF:L3G+
HeLa	M3z3e2FvfGm4aYLhcEBie3OjeR?=		NE\KeXg4OiCqcoO=	Mmf5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiaX7m[YN1\WRiaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC4aYLhcEBqdm[nY4Tpc44h[W[2ZYKgO\|IhcHK\|IHL5JIJmfGFvZ3HsZYN1d3OrZHHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODF4zszNMi=>	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MEW1O\|EoRjF7OEC1OVcyRC:jPh?=
HeLa	M2P0dGFvfGm4aYLhcEBie3OjeR?=		NFLWV2c4OiCqcoO=	NG\hTm1CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHjhdoJwemmwZzDzdIFk\XJicHXweIll\SCDMW[gcZV1[W62IIDyc5RmcW5iaX7m[YN1\WRiaX6gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiC4aYLhcEBqdm[nY4Tpc44h[W[2ZYKgO\|IhcHK\|IHL5JIJmfGFvZ3HsZYN1d3OrZHHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODN6zszNMi=>	Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6MEW1O\|EoRjF7OEC1OVcyRC:jPh?=
cord blood mononuclear cells	NXzpboFJSW62aY\pdoFtKGG\|c3H5		NWXoOFNtPDhiaILz	NIfuPYpCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTDzeYJ1gXCnIFOgbY5n\WO2ZXSgbY4hcHWvYX6gZ49z\CCkbH;v[EBud26xboXjcIVieiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqemGuIILldIxq[2G2aX;uJIFnfGW{IES4JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NE4xODF4N988UU4>	MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
cord blood mononuclear cells	NUfneoUzSW62aY\pdoFtKGG\|c3H5		MWC0PEBpenN?	NEHWcpJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhUEmYMTDzeYJ1gXCnIFPSSlAzZ0GJIHnu[oVkfGWmIHnuJIh2dWGwIHPvdoQh[myxb3SgcY9vd263Y3zlZZIh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD2bZJidCC{ZYDsbYNifGmxbjDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyPUCuNFA2P87:TT6=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEGyN{c,OjB2MESxNlM9N2F-
cord blood mononuclear cells	NX;2WXB5SW62aY\pdoFtKGG\|c3H5		M2W1Z\|Q5KGi{cx?=	NXLqVWE6SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEiLVkGgd5VjfHmyZTDCJIlv\mWldHXkJIlvKGi3bXHuJINwemRiYnzvc4QhdW:wb371Z4xm[XJiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODB7ON88UU4>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEGyN{c,OjB2MESxNlM9N2F-
cord blood mononuclear cells	MXjBcpRqfmm{YXygZZN{[Xl?		NWrU[4xiPDhiaILz	MXnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhS1KIMELfRWchcGG{Yn;ybY5oKHC{b4TlZZNmKHCxbIntc5JxcGm\|bTDheEBKOzZicH;zbZRqd25iYX7kJG01PiCvdYThcpQh\2WwZTDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2wMlA2Pc7:TT6=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEGyN{c,OjB2MESxNlM9N2F-
cord blood mononuclear cells	NGrjb2NCdnSrdnnyZYwh[XO\|YYm=		NHnTe5c1QCCqcoO=	MoPBRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC\|dXL0fZBmKEOURkCyY2FIKGijcnLvdolv\yCycn;0[YF{\SCOM{PJMEBOPD[LLDDBO\|FVKG23dHHueEBo\W6nIHHu[EBxd2y7bX;ydIhqe21iYYSgUVM3KHCxc3n0bY9vKGmwZnXjeIVlKGmwIHj1cYFvKGOxcnSgZoxwd2RibX;uc452[2ynYYKgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkA1QCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmNCCHQ{WwQVAvOjB{zszNMi=>	NVTKV4hZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	MX3BcpRqfmm{YXygZZN{[Xl?		MlXTOFghcHK\|	Ml32RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC\|dXL0fZBmKENiaHHyZo9zcW6pIIDyc5Rm[XOnIFyyN2ktKE12NlmsJGw5QVRibYX0ZY51KGenbnWgZY5lKHCxbIntc5JxcGm\|bTDheEBOOzZicH;zbZRqd25iaX7m[YN1\WRiaX6gbJVu[W5iY3;y[EBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUhNCCHQ{WwQVAvOjd{zszNMi=>	NWGxU2xyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
cord blood mononuclear cells	NILOW3VCdnSrdnnyZYwh[XO\|YYm=		NGnQXHI1QCCqcoO=	MUPBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSiCqYYLic5JqdmdicILveIVie2ViREOwUkwhVTR4STygRVcyXCCjbnSgWlc4USCvdYThcpQh\2WwZTDhcoQheG:ueX3vdpBpcXOvIHH0JG0{PiCyb4PpeIlwdiCxZjDwdo91\WG\|ZTDpcoZm[3SnZDDpckBpfW2jbjDjc5JlKGKub3;kJI1wdm:wdXPs[YFzKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gZYZ1\XJiNEigbJJ{KGK7IHz1Z4ktKEWFNUC9NU4yOzoQvF2u	M2fHc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEC0NVI{Lz5{MESwOFEzOzxxYU6=
cord blood mononuclear cells	Ml25RY51cX[rcnHsJIF{e2G7		MWW0PEBpenN?	MUnBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKHO3YoT5dIUhSiCqYYLic5JqdmdicILveIVie2ViREOwUkwhVDN\|STygUVQ3USxiTki4SEBufXSjboSg[4Vv\SCjbnSgdI9tgW2xcoDobZNuKGG2IFmzOkBxd3OrdHnvckBqdm[nY4Tl[EBqdiCqdX3hckBkd3KmIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yhfmm{YXygdoVxdGmlYYTpc44h[W[2ZYKgOFghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZItKEWFNUC9NU41PjQQvF2u	MnfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
cord blood mononuclear cells	M{nOfGFvfGm4aYLhcEBie3OjeR?=		MVu0PEBpenN?	NV;ncGFYSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDzeYJ1gXCnIFOgbIFz[m:{aX7nJJBzd3SnYYPlJGQ{OE5uIFWzOWctKEl6NW[sJGw6OE1ibYX0ZY51KGenbnWgZY5lKHCxbIntc5JxcGm\|bTDheEBKOzZicH;zbZRqd25iaX7m[YN1\WRiaX6gbJVu[W5iY3;y[EBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdoFtKHKncHzpZ4F1cW:wIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{LDDFR\|UxRTNwNEez{txONg>?	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
TZM-bl	NIjMZZFCdnSrdnnyZYwh[XO\|YYm=		MkDIOFghcHK\|	NXi0VpBHSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDzeYJ1gXCnIFKgbIFz[m:{aX7nJJBzd3SnYYPlJJBwdHmvb4LwbIl{dSCjdDDNN\|YheG:\|aYTpc44hcW6oZXP0[YQhcW5iaIXtZY4hXFqPLXLsJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25iYX\0[ZIhPDhiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?=	NX3EVXhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQyOjNpPkKwOFA1OTJ\|PD;hQi=>
TZM-bl	M{H0TWFvfGm4aYLhcEBie3OjeR?=		NFrpOms1QCCqcoO=	M{G5V2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFic4XieJlx\SCFUl[wNn9CTyCqYYLic5JqdmdicILveIVie2VicH;sfY1wenCqaYPtJIF1KEl\|NjDwc5NqfGmxbjDpcoZm[3SnZDDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXKjbDDy[ZBtcWOjdHnvckBi\nSncjC0PEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	MnvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
TZM-bl	M2HDUmFvfGm4aYLhcEBie3OjeR?=		NH:3dZI1QCCqcoO=	M{P1ZmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFic4XieJlx\SCEIHjhdoJwemmwZzDwdo91\WG\|ZTDwc4x6dW:{cHjpd40h[XRiSUO2JJBwe2m2aX;uJIlv\mWldHXkJIlvKGi3bXHuJHRbVS2kbDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFQ5KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	MlPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MESxNlMoRjJyNEC0NVI{RC:jPh?=
MT4	NGDHW3BCdnSrdnnyZYwh[XO\|YYm=			M4HpW2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJdqdGRidInw[UBJUVZzIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyCkeTDNWHQh[XO\|YYmsJGVEPTB;MD6wOFXPxE1w	NY[2ZoQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	MYPBcpRqfmm{YXygZZN{[Xl?			NEGyZ5hCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExUS:OMkTJM201PklxVkiyTU9KQDSYIH31eIFvfCCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNic3Xs[YN1\WRiYX\0[ZIhPTBicHHzd4Fo\XNib3[gS3JNNTJzNjDifUBOXFRiYYPzZZktKEWFNUC9NE4yO87:TT6=	Mlf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	M3vTWmFvfGm4aYLhcEBie3OjeR?=	NUfOfZQzOSC3TR?=		NEnzNXBCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\NMGkwWTZzUTDteZRidnRiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IIPlcIVkfGWmIHH0JFEhfU1ib3[gS3JNNTN7NjDifUBOXFRiYYPzZZktKEWFNUC9NE4zOs7:TT6=	NWjIR4RuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|k3OTJpPkKwOFM6PjF{PD;hQi=>
MT4	MoLBRY51cX[rcnHsJIF{e2G7	NYT5UpFiOSC3TR?=		NETI[mlCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHX4dJJme3OrbnegdJJwfGWjc3WgUFExTi:PNE\JM3Q6OVNibYX0ZY51KGmwZnXjeIVlKGmwIHj1cYFvKE2WNDDj[YxteyC\|ZXzlZ5Rm\CCjdDCxJJVOKG:oIFfSUE0zPDZiYomgUXRVKGG\|c3H5MEBGSzVyPUCuNlnPxE1w	Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2M{m2NVIoRjJyNEO5OlEzRC:jPh?=
MT4	NHfYT2FCdnSrdnnyZYwh[XO\|YYm=	NF[3fYM2KHWP		NXnLPZpjSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDlfJBz\XO\|aX7nJJBzd3SnYYPlJGwyOEZxTUS2TU9KPTCYL1G3NXYwUTh2Vj;MPVBOKG23dHHueEBqdm[nY4Tl[EBqdiCqdX3hckBOXDRiY3XscJMhe2WuZXP0[YQh[XRiNTD1UUBw\iCjbYDy[Y5ifmm{IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlPPxE1w	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR\|OU[xNkc,OjB2M{m2NVI9N2F-
MT4	NWjXZ\|dUSW62aY\pdoFtKGG\|c3H5	M3;jOVUhfU1?		MXXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwSk9OPD[LL1m1OHYwXjh{QTDteZRidnRiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy\|IIPlcIVkfGWmIHH0JFUhfU1ib3[gUI9xcW6jdnnyJIJ6KE2WVDDhd5NigSxiRVO1NF0xNjN{zszNMi=>	M1;3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEO5OlEzLz5{MESzPVYyOjxxYU6=
MT4	MULBcpRqfmm{YXygZZN{[Xl?	NI\TUJMyKHWP		MYLBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwSk9OPD[OL1m1NHYwSTdzVn31eIFvfCCrbn\lZ5Rm\CCrbjDoeY1idiCPVESgZ4VtdHNic3Xs[YN1\WRiYYSgNUB2VSCxZjDHVmwuOjh4IHL5JG1VXCCjc4PhfUwhTUN3ME2wMlM4\|ryPLh?=	NIOybm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzPVYyOid-MkC0N\|k3OTJ:L3G+
MT4	MV\BcpRqfmm{YXygZZN{[Xl?	MnzROUB2VQ>?		MWjBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDITXYyKGW6cILld5NqdmdicILveIVie2ViTEGwTU9IPDiYL1m1OHYwSTdzVj;JPFRXN0x7MF2gcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDz[Yxm[3SnZDDheEA2KHWPIH;mJJNieXWrbnH2bZIh[nliTWTUJIF{e2G7LDDFR\|UxRTBwNUJOwG0v	NHjpTpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzPVYyOid-MkC0N\|k3OTJ:L3G+
BESM	MWHBcpRqfHK7cHHuc5NwdWGuIHHzd4F6		M{j2ZVg5KGi{cx?=	MXXBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IHHnZYlve3RiVIL5dIFvd3OxbXGgZ5J2gmliYX3hd5Rq\2:2ZYOgbY5n\WO2ZXSgbY4hSkWVTTDj[YxteyCvZXHzeZJm\CCjZoTldkA5QCCqcoOgdI9{fGmwZnXjeIlwdiCkeTDIWHMh[XO\|YYmsJGVEPTB;MUNOwG0v	NV7xRmpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OFc5OTlpPkKwOVQ4QDF7PD;hQi=>
BESM	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		Mo\3PFghcHK\|	MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBDTVOPIHPlcIx{KGGodHXyJFg5KGi{czDifUBJXFNiYYPzZZktKEWFNUC9N\|LPxE1w	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV2N{ixPUc,OjB3NEe4NVk9N2F-
CMEC/D3	M2W5NmZ2dmO2aX;uJIF{e2G7		MVSzNEBucW6\|	M4[3WmlvcGmkaYTpc44hd2ZiUD3ndEBqdiCqdX3hckBEVUWFL1SzJINmdGy\|IIXzbY5oKE6ERD3BZoEh[XNic4Xid5Rz[XSnIHHmeIVzKDNyIH3pcpMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVEvP87:TT6=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTVyNUmyPEc,OzF3MEW5Nlg9N2F-
CMEC/D3	Mnr4SpVv[3Srb36gZZN{[Xl?		Mn\UN\|AhdWmwcx?=	M1;zfWlvcGmkaYTpc44hd2ZiUD3ndEBqdiCqdX3hckBEVUWFL1SzJINmdGy\|IIXzbY5oKGOjbHPlbY4uSU1iYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTMQvF2u	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
12D7-MDR	MWDGeY5kfGmxbjDhd5NigQ>?		NE[4OZY{OCCvaX7z	MXTJcohq[mm2aX;uJI9nKFBvZ4CgbY4hcHWvYX6gNVJFPy2PRGKgZ4VtdHNidYPpcochVkKGLVHiZUBieyC\|dXLzeJJifGViYX\0[ZIhOzBibXnud{BjgSCobH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9OU45\|ryPLh?=	NUTUTYZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1NFU6OjhpPkOxOVA2QTJ6PD;hQi=>
12D7-MDR	MoXaSpVv[3Srb36gZZN{[Xl?		M1TPc\|MxKG2rboO=	Mk\DTY5pcWKrdHnvckBw\iCSLXfwJIlvKGi3bXHuJFEzTDdvTVTSJINmdGy\|IIXzbY5oKGOjbHPlbY4uSU1iYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTlwMd88UU4>	Mo\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
12D7	Ml\zRY51cX[rcnHsJIF{e2G7		NHnsSVg{KGSjeYO=	M1PqTmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTFHJJIlv\mWldHXkJIlvKGi3bXHuJFEzTDdiY3XscJMhd3[ncnX4dJJme3OrbnegdE1oeCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hWDJ2IHzleoVtKGG2IEG6NUBz[XSrbzDv[kB1\XO2IHPvcZBwfW6mIITvJIFj[WOjdnnyJIlv[3WkYYTl[EBnd3JiMzDkZZl{KG[xbHzve4VlKGK7IH\vcIxwf2WmIHL5JJJmeGyjY3Xt[Y51KG:oIH\y[ZNpKG2nZHn1cUBkd262YXnubY5oKGOxbYDveY5l	MoXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
12D7	MmDhRY51cX[rcnHsJIF{e2G7	NWjUO2tTOC5yODD0c{AyNjJ3IIXN	NV33clVLOyCmYYnz	M2DVXGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiTFHJJIlv\mWldHXkJIlvKGi3bXHuJFEzTDdiY3XscJMhd3[ncnX4dJJme3OrbnegdE1oeCCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hWDJ2IHzleoVtKGG2IECuNFghfG9iMT6yOUB2VSCrbnP1ZoF1\WRiZn;yJFMh\GG7czDmc4xtd3enZDDifUBz\XCuYXPlcYVvfCCxZjDmdoV{cCCvZXTpeY0h[2:wdHHpcolv\yClb33wc5Vv\CCjbnSgcYVie3W{ZXSgZYZ1\XJiMzDkZZl{KGK7IFXMTXNC	MmLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3MEW5NlgoRjNzNUC1PVI5RC:jPh?=
SJ-GBM2	Mo\hdWhVWyCjc4PhfS=>			Mn3sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	M{PSW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MVzxTHRUKGG\|c3H5			NWnwfo1MeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NHnZNGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	NEXmZotyUFSVIHHzd4F6			MmLzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NITIemU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	MlzidWhVWyCjc4PhfS=>			M{\X[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	NFHs[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M2e0NpFJXFNiYYPzZZk>			MkC2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	M1zVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NEnvNlFyUFSVIHHzd4F6			NFnJWZByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MlSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M2jBTJFJXFNiYYPzZZk>			NICzS\|lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	M4HsbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MT2	NVftepNtSW62aY\pdoFtKGG\|c3H5		MorBOUBl[Xm\|	MlrQRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4Sge4lt\CC2eYDlJGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIF{e2W\|c3XkJIF{KH[rcoXzMYlv\HWlZXSgZ5l1d3CjdHjpZ{Bm\m[nY4SgZYZ1\XJiNTDkZZl{KGK7IGjUWEBie3OjeTygSWM2OD1yLkCwOFnPxE1w	M{P1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU5PC9pPlPoSW1DVDxxYU6=
HepG2	NF;Q[I9EgXSxdH;4bYNqfHliYYPzZZk>		MoSyOUBl[Xm\|	NH;lWm1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNTDkZZl{KGK7IGjUWEBie3OjeTygR2M2OD15LkVOwG0v	Ml;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVg1Nyd-Q3jFUWJNRC:jPh?=
skeletal myoblast cells	NGf6ZXhEgXSxdH;4bYNqfHliYYPzZZk>		NF:xcFM4OiCqb4Xydy=>	M4jPS2RPTEl8IFP5eI91d3irY3n0fUBqdiCYaYTyc{whPzJiaH;1dkwhcW5icnH0JJNs\WyndHHsJI16d2KuYYP0JINmdGy\|LDDJR\|UxRTF{LkC1{txONg>?	M2DDWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU5PC9pPlPoSW1DVDxxYU6=
MT2	NWL6b5hpS3m2b4TvfIlkcXS7IHHzd4F6		NVjVcYFvPSCmYYnz	NXWxUmpZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVVR{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB3IHThfZMh[nliWGTUJIF{e2G7LDDDR\|UxRTF7LkJOwG0v	M3TpO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU5PC9pPlPoSW1DVDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Growth inhibition assay	Cell viability; PubMed: 22271897 Haematologica Histograms show the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines treated with nelfinavir (1 μM to 10 μM).	22271897
Western blot	p-eIF2Aα / eIF2Aα / ATF4 / GRP78 / CHOP ; PubMed: 21697087 J Biol Chem U251 cells were mock-treated (0) or treated with Nelfinavir (NFV) (20 μm) for 4 or 24 h then whole cell lysates were immunoblotted for P-eIF2α, eIF2α, ATF4, GRP78, CHOP, and Ran, as indicated. SOD1 / SOD2 / catalase ; PubMed: 27280849 PLoS One Protein lysates derived from MDA-MB231, MCF-7, or breast epithelial cells, treated with 10 μM nelfinavir for the indicated time points, were immunoblotted with anti- SOD1, anti-SOD2 and anti-catalase. Beta-actin was used as loading control. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Western blot of the indicated cell lines treated with 10 μM nelfinavir for 24 hr for PAX3, MITF, and ERK2.	21697087 27280849 26977879
Immunofluorescence	LC3 / p62 ; PubMed: 27330277 Drug Des Devel Ther Immunofluorescence of cells treated with control 0.1% dimethyl sulfoxide or 10 μM nelfinavir for 24 hours. Scale bars indicate 10 μm and apply to all images. Punctate LC3 were quantified as autophagosomes and punctate p62 were quantified as sequestosomes, P<0.01, *P<0.001. (C and D) Western blot of lysates prepared following 24 hours of drug treatment. Nelfinavir was used at 10 μM and the autophagy clearance inhibitor chloroquine at 10 μM. PAX3 / MITF ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for PAX3 and MITF in WM266-4 cells left untreated or treated with 10 μM nelfinavir for 24 hr; scale bars, 50 μm. p-SMAD2 ; PubMed: 26977879 Cancer Cell Immunofluorescence analysis for phospho-SMAD2 in melanoma cells treated with nelfinavir; scale bars, 10 μm	27330277 26977879

In vivo

In vivo studies indicate that AG1343 is well absorbed orally in a variety of species and possesses favorable pharmacokinetic properties in humans. Initial investigation of the compound in fed rats indicated an oral bioavailability of 43%. In contrast, the oral bioavailability was significantly reduced in fasted rats to 29%. Nelfinavir demonstrated significant oral bioavailabilability across a range of species including dogs (47%), marmosets (17%), and cynomolgus monkeys (26%). It has a long plasma half-life after oral dosing that is likely due to a combination of slow dissolution and absorption. nelfinavir is well absorbed in humans particularly when administered with food and possesses minimal and easily managed side effects^[1].

Protocol

Animal Research: ^[1]	- Collapse Animal Models: Sprague-Dawley rats Dosages: 12.5 to 25 mg/kg (i.v); 25 to 50 mg/kg (oral) Administration: i.v and oral administration (Only for Reference)

References

[1] Kaldor SW, et al.J Med Chem, 1997,40(24):3979-85.

Solubility (25°C)

In vitro	DMSO	100 mg/mL (150.62 mM)
	Water	Insoluble
	Ethanol	''100 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Nelfinavir (AG 1343) Mesylate SDF

Molecular Weight	663.89
Formula	C₃₃H₄₉N₃O₇S₂
CAS No.	159989-65-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Viracept
Smiles	CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HIV Protease Signaling Pathway Map

Related HIV Protease Products

Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
Ledipasvir (GS5885) ^New

Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection.
Ritonavir (ABT-538)

Ritonavir (ABT-538, A 84538, RTV, Norvir, Norvir Softgel) is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. Ritonavir induces apoptosis.
Lopinavir (ABT-378)

Lopinavir (ABT-378) is a potent HIV protease inhibitor with K_i of 1.3 pM in a cell-free assay.
Darunavir Ethanolate

Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.
Amprenavir (VX-478)

Amprenavir (VX-478, 141W94, KVX-478) is a potent PXR-selective agonist, and an HIV protease inhibitor, used to treat HIV.
Atazanavir (BMS-232632) Sulfate

Atazanavir Sulfate (BMS-232632) is a HIV protease inhibitor with K_i of 2.66 nM in a cell-free assay.

Features:Atazanavir is generally more potent than other HIV-1 Prt inhibitors, including IDV, SQV, RTV, NFV, and APV.
MG-132

MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Nelfinavir (AG 1343) Mesylate